Contents

Current Drug Targets, Volume 10 - Number 1

Biomarkers, Critical Disease Pathways, Drug Targets, and Alternative Medicine in Male Breast Cancer

, 10(1): 1 - 8

Debmalya Barh


DOI: 10.2174/138945009787122842




NPY Signalling Pathway in Bone Homeostasis: Y1 Receptor as a Potential Drug Target

, 10(1): 9 - 19

D. M. Sousa, H. Herzog and M. Lamghari


DOI: 10.2174/138945009787122888




Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events

, 10(1): 20 - 25

S. Novo, M. Lunetta, S. Evola and G. Novo


DOI: 10.2174/138945009787122897




Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus

, 10(1): 26 - 37

Ewa Robak and Tadeusz Robak


DOI: 10.2174/138945009787122833




PDGF-D Signaling: A Novel Target in Cancer Therapy

, 10(1): 38 - 41

Zhiwei Wang, Dejuan Kong, Yiwei Li and Fazlul H. Sarkar


DOI: 10.2174/138945009787122914




Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets

, 10(1): 42 - 50

Karly C. Sourris and Josephine M. Forbes


DOI: 10.2174/138945009787122905




HIV: A Raft-Targeting Approach for Prevention and Therapy Using Plant-Derived Compounds (Review)

, 10(1): 51 - 59

S. P. Verma


DOI: 10.2174/138945009787122851




Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations

, 10(1): 60 - 70

A. R. De Gaudio, S. Rinaldi, C. Chelazzi and T. Borracci


DOI: 10.2174/138945009787122879




Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

, 10(1): 71 - 87

Rajesh Gupta, Sameer S. Walunj, Ranjeet K. Tokala, Kishore V.L. Parsa, Santosh Kumar Singh and Manojit Pal


DOI: 10.2174/138945009787122860




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science